Core Viewpoint - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement project in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Participation - Huarun Pharmaceutical and its wholly-owned subsidiaries, Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huarun Pharmaceutical (Rizhao) Co., Ltd., actively engaged in the bidding process for the procurement project [1] - The project is identified as "LH-YD2025-1" and involves both Western medicine and traditional Chinese medicine [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has announced the selection results, confirming that Huarun Pharmaceutical's products, including mixed sugar electrolyte injection, betahistine hydrochloride sodium injection, and hydroxyethyl starch 130/0.4 sodium chloride injection, have been chosen for this procurement [1]

Core Viewpoint - Huaneng Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement, specifically for Western medicine and traditional Chinese medicine [1] - The procurement project number is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with projected sales of 823,200 yuan, accounting for 0.06% of the company's total revenue in 2024 [1] - Betahistine hydrochloride sodium injection with projected sales of 2,220,300 yuan, representing 0.16% of total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with projected sales of 9,995,400 yuan, making up 0.74% of total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, which constitutes 0.96% of the company's total revenue [1]

Core Viewpoint - Huarun Pharmaceutical (300110.SZ) and its wholly-owned subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Procurement Participation - The company and its subsidiaries actively engaged in the bidding process for the "3+N" alliance procurement project (Project No: LH-YD2025-1) [1] - The Tianjin Pharmaceutical Procurement Center recently announced the selection results, confirming the company's products as winners in this procurement [1] Group 2: Selected Products and Revenue Impact - The selected products include: - Mixed sugar electrolyte injection with a projected sales revenue of 823,200 yuan for 2024, accounting for 0.06% of the company's total revenue [1] - Betahistine hydrochloride sodium injection with a projected sales revenue of 2,220,300 yuan for 2024, accounting for 0.16% of the company's total revenue [1] - Hydroxyethyl starch 130/0.4 sodium chloride injection with a projected sales revenue of 9,995,400 yuan for 2024, accounting for 0.74% of the company's total revenue [1] - The total projected sales revenue from these selected products for 2024 is 13,038,900 yuan, representing 0.96% of the company's total revenue [1]

Core Insights - Huarun Pharmaceutical and its subsidiaries have successfully participated in the bidding for the "3+N" alliance procurement in the Beijing-Tianjin-Hebei region, securing contracts for several products [1] Group 1: Company Performance - The selected products are expected to generate a total sales revenue of 13.0389 million yuan in 2024, accounting for 0.96% of the company's total revenue for the year [1] - The revenue breakdown for the selected products includes: - Mixed sugar electrolyte injection: 823,200 yuan (0.06% of total revenue) - Betahistine hydrochloride sodium injection: 2,220,300 yuan (0.16% of total revenue) - Hydroxyethyl starch 130/0.4 sodium chloride injection: 9,995,400 yuan (0.74% of total revenue) [1] Group 2: Product Details - The selected products and their specifications include: - Mixed sugar electrolyte injection (500ml) priced at 15.29 yuan per bag, used for hydration and electrolyte maintenance [2] - Betahistine hydrochloride sodium injection (0.02g) priced at 5.76 yuan per bottle, primarily for Meniere's disease and related conditions [2] - Hydroxyethyl starch 130/0.4 sodium chloride injection available in multiple specifications, priced between 3.56 and 6.05 yuan per bag, used for treating and preventing blood volume deficiency [2]

Core Viewpoint - The company and its wholly-owned subsidiaries have actively participated in the bidding for the "3+N" alliance volume-based procurement project in the Beijing-Tianjin-Hebei region, achieving success in securing contracts for several products [1] Group 1: Company Participation - The company, along with its wholly-owned subsidiary Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huaren Pharmaceutical (Rizhao) Co., Ltd., has engaged in the bidding process for the volume-based procurement [1] - The project number for the procurement is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has recently announced the results of the procurement, confirming that the company's products have been selected [1] - The selected products include mixed sugar electrolyte injection, betahistine hydrochloride sodium chloride injection, and hydroxyethyl starch 130/0.4 sodium chloride injection [1]

Core Viewpoint - The company and its wholly-owned subsidiaries have actively participated in the bidding for the "3+N" alliance volume-based procurement project in the Beijing-Tianjin-Hebei region, achieving success in securing contracts for several products [1] Group 1: Company Participation - The company, along with its wholly-owned subsidiaries Guangxi Yuyuan Pharmaceutical Co., Ltd. and Huaren Pharmaceutical (Rizhao) Co., Ltd., has engaged in the bidding process for the volume-based procurement [1] - The project number for the procurement is LH-YD2025-1, indicating a structured approach to the bidding process [1] Group 2: Procurement Results - The Tianjin Pharmaceutical Procurement Center has recently announced the results of the procurement, confirming that the company's products have been selected [1] - The selected products include mixed sugar electrolyte injection, betahistine hydrochloride sodium chloride injection, and hydroxyethyl starch 130/0.4 sodium chloride injection [1]